Prescribing information can be found at the bottom of the page

Why choose Invokana (canagliflozin) - After first line, take a firm line
Invokana Cardiovascular Icon

Cardiovascular Outcomes

Reduce the long-term risk of CV events with Invokana

  • CANVAS showed a 14% relative reduction in risk for MACE among a mix of both primary and secondary prevention patients.
    HR: 0.86 (95% Cl, 0.75-0.97)1 ARR: 4.6 fewer events per 1000 patient-years.
Graph - Death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke

All-cause mortality was the first secondary endpoint in the pre-specified hypothesis testing sequence.
Because analysis of this endpoint failed to show superiority for Invokana, hypothesis testing could not be carried out for the other secondary endpoints.
Simplified statistics (hazard ratios and nominal 95% CIs) are shown for these additional endpoints, but these are not statistically significant.

  • CANVAS also showed a 33% relative reduction in risk of hospitalisation for heart failure among a mix of both primary and secondary prevention patients.
    HR: 0.67 (95% Cl, 0.52-0.87)1 ARR: 3.2 fewer events per 1000 patient-years.
References
  1. Neal B, et al. N Engl J Med. 2017;377(7):644-57